CLINICAL TRIALS PROFILE FOR ILOPROST
✉ Email this page to a colleague
All Clinical Trials for iloprost
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004786 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis | Completed | University of Pittsburgh | Phase 3 | 1995-12-01 | OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis. |
| NCT00004786 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis | Completed | National Center for Research Resources (NCRR) | Phase 3 | 1995-12-01 | OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis. |
| NCT00084409 ↗ | Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-11-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease. |
| NCT00084409 ↗ | Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease | Completed | University of Colorado, Denver | Phase 2 | 2001-11-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease. |
| NCT00086463 ↗ | Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) | Completed | Actelion | Phase 2 | 2004-06-01 | The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM). |
| NCT00109681 ↗ | Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis | Completed | Actelion | Phase 2 | 2005-04-01 | The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure. The secondary purpose is to evaluate the effectiveness of this treatment in subjects with this disease. |
| NCT00120380 ↗ | Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH) | Terminated | Hannover Medical School | Phase 4 | 2004-09-01 | The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist bosentan. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for iloprost
Condition Name
Clinical Trial Locations for iloprost
Trials by Country
Clinical Trial Progress for iloprost
Clinical Trial Phase
Clinical Trial Sponsors for iloprost
Sponsor Name
